Drugs in MeSH Category Anticestodal Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	NICLOCIDE	niclosamide	TABLET, CHEWABLE;ORAL	018669-001	May 14, 1982		DISCN	No	No
Cipla Ltd	ALBENDAZOLE	albendazole	TABLET;ORAL	210434-001	Sep 21, 2018		DISCN	No	No
Dr Reddys	ALBENDAZOLE	albendazole	TABLET;ORAL	211034-001	Jan 26, 2021	AB	RX	No	Yes
Impax Labs Inc	ALBENZA	albendazole	TABLET;ORAL	020666-001	Jun 11, 1996		DISCN	Yes	No
Msn	ALBENDAZOLE	albendazole	TABLET;ORAL	213435-001	Jan 21, 2021	AB	RX	No	No
Strides Pharma	ALBENDAZOLE	albendazole	TABLET;ORAL	210011-001	Dec 7, 2018		DISCN	No	No
Zydus Pharms	ALBENDAZOLE	albendazole	TABLET;ORAL	208979-001	Dec 14, 2018	AB	RX	No	No

Anticestodal Agents Market Analysis and Financial Projection

The global market for anticestodal agents is experiencing significant growth driven by rising parasitic infections and strategic innovations, while evolving patent landscapes present both opportunities and challenges for market players.

Market Dynamics

Market Size and Growth Projections

• The Antiparasitics Drugs Market, which includes anticestodal agents, was valued at $24 billion in 2022 and is projected to reach $38.25 billion by 2030, growing at a 6% CAGR[4][12].
• The broader Anti-Infective Treatment Market (encompassing anticestodal therapies) is expanding from $76.5 billion in 2022 to an estimated $101.3 billion by 2030 at a 4.1% CAGR[1].

Key Growth Drivers

• Parasitic Disease Burden: Over 241 million children in India alone are at risk of intestinal worms, driving government campaigns like the National Deworming Initiative[14].
• Strategic Collaborations: Partnerships such as Corteva Agriscience and Stoller’s distribution of bionematicides demonstrate cross-industry efforts to combat parasitic resistance[4].
• Novel Formulations: Recent FDA approvals like Natroba Topical Suspension (spinosad) for scabies highlight advancements in treatment accessibility[4].

Emerging Opportunities

• Combination Therapies: Trials combining beta-lactams with beta-lactamase inhibitors show enhanced efficacy against resistant strains[1].
• Pediatric Focus: Development of child-friendly formulations addresses unmet needs in treating young populations[9].

Patent Landscape and Innovations

Key Patent Trends

Patent Focus	Examples	Impact
Formulation Improvements	Nano-particle praziquantel for better solubility (WO2015071668A1)[11]	Extends patent lifecycle while improving bioavailability
Drug Repurposing	Avasimibe (discontinued dyslipidemia drug) repurposed for Niemann-Pick disease (WO2013/016315)[8]	Lowers R&D costs by leveraging existing compounds
Combination Therapies	Ombitasvir/grazoprevir combinations for HCV (EP2797594A)[5]	Broadens therapeutic applications through synergistic effects

Challenges

• Generic Competition: Bedaquiline’s patent filings in high-TB-burden countries could delay affordable generics despite public health needs[2].
• Resistance Mechanisms: Overreliance on albendazole has led to resistance, necessitating novel targets like STAT3 inhibitors in development[3].

Regional Insights

• Asia-Pacific: Dominates growth due to high disease prevalence and initiatives like India’s $1.3 billion allocation for neglected tropical diseases[14].
• North America: Leads in innovation, with entities like Rush University patenting repurposed therapies (e.g., gemfibrozil for Krabbe disease)[8].

“The future of anticestodal treatment lies in balancing patent protections with equitable access, particularly in low-income regions.” – Analysis of WHO guidelines on antiparasitic drug distribution[2][5].

Future Outlook

The anticestodal market is pivoting toward biologics and targeted therapies to address resistance, with CRISPR-based gene editing and immunomodulators entering preclinical pipelines[9]. Concurrently, AI-driven drug discovery platforms aim to shorten development timelines for next-generation agents[12].

Takeaway: Stakeholders must navigate complex patent strategies while prioritizing affordable access to meet global health demands.

References

1. https://github.com/Aniketshelar123/Strategic-Insights-Analyst/blob/main/Anti-Infective-Treatment-Market-Key-Trends.md
2. https://unitaid.org/uploads/TMC_207_Patent_Landscape.pdf
3. https://patentimages.storage.googleapis.com/3d/14/46/5b60c1e14b7980/US9562002.pdf
4. https://www.databridgemarketresearch.com/reports/global-antiparasitics-drugs-market
5. https://unitaid.org/uploads/Grazoprevir_Patent_Landscape.pdf
6. https://www.pharmacompass.com/active-pharmaceutical-ingredients/albendazole
7. https://www.businesswire.com/news/home/20221104005321/en/Antiparasitic-Drugs-Global-Market-Report-2022-Government-Non-Profit-and-Market-Player-Initiatives-to-Boost-Adoption-Bode-Well-For-Growth---ResearchAndMarkets.com
8. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGREPO.24.1.0012
9. https://www.openpr.com/news/3647733/antiparasitic-drugs-market-forecast-dynamics-size-share
10. https://pubmed.ncbi.nlm.nih.gov/15282238/
11. https://patents.google.com/patent/WO2015071668A1/en
12. https://www.coherentmarketinsights.com/market-insight/antiparasitic-drugs-market-3782
13. https://veteriankey.com/anticestodal-and-antitrematodal-drugs/
14. https://www.databridgemarketresearch.com/reports/global-anthelmintics-market